ZYMEWORKS INC (US)(ZYME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ZYME ZYMEWORKS INC (US)

Pre-Mkt 12-11 04:03:48 EST

25.87

+0.07

+0.25%

High26.18	Low25.45	Vol698.81K
Open25.78	D1 Closing25.81	Amplitude2.83%
Mkt Cap1.94B	Tradable Cap990.81M	Total Shares74.84M
T/O18.05M	T/O Rate1.82%	Tradable Shares38.30M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ZYME","market":"US","secType":"STK","nameCN":"ZYMEWORKS INC (US)","latestPrice":25.87,"timestamp":1765400400000,"preClose":25.805,"halted":0,"volume":698805,"delay":0,"floatShares":38299500,"shares":74836534,"eps":-0.84316,"marketStatus":"Pre-Mkt","change":0.065,"latestTime":"12-11 04:03:48 EST","open":25.78,"high":26.18,"low":25.45,"amount":18049230.992745,"amplitude":0.028289,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.84316,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1765463400000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1493352000000,"exchange":"NASDAQ","adjPreClose":25.87,"postHourTrading":{"tag":"盘后","latestPrice":25.87,"preClose":25.87,"latestTime":"19:07 EST","volume":10584,"amount":273805.14,"timestamp":1765411637290},"volumeRatio":1.1030942251914402,"impliedVol":0.6702,"impliedVolPercentile":0.4137},"requestUrl":"/m/hq/s/ZYME/tweets","defaultTab":"tweets","newsList":[{"id":"2588028823","title":"Zymeworks Initiated at Market Outperform by Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2588028823","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588028823?lang=en_us&edition=fundamental","pubTime":"2025-12-04 00:08","pubTimestamp":1764778080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZYME/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 03, 2025 11:08 ET (16:08 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZYME","BK4139"],"gpt_icon":0},{"id":"2588066991","title":"Zymeworks Showcases Pipeline Advances at ASCO GI and J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2588066991","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588066991?lang=en_us&edition=fundamental","pubTime":"2025-12-03 05:05","pubTimestamp":1764709516,"startTime":"0","endTime":"0","summary":"Zymeworks Inc. will participate in the ASCO Gastrointestinal Cancers Symposium, taking place January 8-10, 2026, in San Francisco, CA. The company will present a Trial-in-Progress poster on ZW251, a novel GPC3-targeted antibody-drug conjugate for hepatocellular carcinoma, during the Trials in Progress Poster Session on January 9, 2026. Additionally, Zymeworks' management will present at the J.P. Morgan Healthcare Conference on January 14, 2026, at 3:00 pm PT.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zymeworks Inc. published the original content used to generate this news brief via GlobeNewswire  on December 02, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL8XQLmg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","BK4139","LU2210149790.SGD","BK4112","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2095319765.USD","IE00B64PRP62.GBP","BK4585","BK4588","ZYME","NDAQ","LU2210150020.SGD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2586002272","title":"Zymeworks (ZYME) Is Up 13.8% After Positive Zanidatamab Trial and Share Buyback Plan - What's Changed","url":"https://stock-news.laohu8.com/highlight/detail?id=2586002272","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586002272?lang=en_us&edition=fundamental","pubTime":"2025-11-28 15:22","pubTimestamp":1764314576,"startTime":"0","endTime":"0","summary":"Zymeworks Inc. recently announced positive topline results from its Phase 3 HERIZON-GEA-01 trial of its lead HER2-targeted antibody, zanidatamab, for first-line treatment of HER2-positive gastroesophageal adenocarcinoma, alongside a new share repurchase program of up to US$125 million and leadership changes including the appointment of an Acting Chief Investment Officer.\nA unique aspect is Zymeworks’ ongoing shift toward a royalty-driven business model, leveraging major partnerships and...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zyme/zymeworks/news/zymeworks-zyme-is-up-138-after-positive-zanidatamab-trial-an","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zyme/zymeworks/news/zymeworks-zyme-is-up-138-after-positive-zanidatamab-trial-an","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ZYME","BK4139"],"gpt_icon":0},{"id":"2585650084","title":"Zymeworks Inc. to Participate in Major Healthcare Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2585650084","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585650084?lang=en_us&edition=fundamental","pubTime":"2025-11-24 19:00","pubTimestamp":1763982007,"startTime":"0","endTime":"0","summary":"Zymeworks Inc. will participate in the Evercore 8th Annual Healthcare Conference on December 2, 2025, and the Citi 2025 Global Healthcare Conference on December 3, 2025, both in Miami, Florida. The company's management will join one-on-one meetings and fireside chats at these events.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zymeworks Inc. published the original content used to generate this news brief via GlobeNewswire  on November 24, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL9XWtqS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00B3QW5Z07.USD","ZYME","BK4139","BK4127","LU0314104364.USD","IE00BGHQF748.EUR","LU2210149790.SGD","EVR","LU2095319765.USD","BK4585","IE00BKPKM429.USD","BK4112","BK4588","IE00B64PRP62.GBP","NDAQ"],"gpt_icon":0},{"id":"2585705931","title":"LifeSci Capital Reaffirms Their Buy Rating on Zymeworks (ZYME)","url":"https://stock-news.laohu8.com/highlight/detail?id=2585705931","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585705931?lang=en_us&edition=fundamental","pubTime":"2025-11-22 23:35","pubTimestamp":1763825714,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Charles Zhu maintained a Buy rating on Zymeworks today and set a price target of $34.00. Zhu covers the Healthcare sector, ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lifesci-capital-reaffirms-their-buy-rating-on-zymeworks-zyme-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lifesci-capital-reaffirms-their-buy-rating-on-zymeworks-zyme-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZYME"],"gpt_icon":0},{"id":"2584787259","title":"Zymeworks price target raised to $40 from $37 at Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2584787259","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584787259?lang=en_us&edition=fundamental","pubTime":"2025-11-20 03:45","pubTimestamp":1763581516,"startTime":"0","endTime":"0","summary":"Leerink raised the firm’s price target on Zymeworks (ZYME) to $40 from $37 and keeps an Outperform rating on the shares after the company announced...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zymeworks-price-target-raised-to-40-from-37-at-leerink-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zymeworks-price-target-raised-to-40-from-37-at-leerink-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZYME","BK4139"],"gpt_icon":0},{"id":"2584974040","title":"A Look at Zymeworks (ZYME) Valuation After Breakthrough Phase 3 Cancer Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2584974040","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584974040?lang=en_us&edition=fundamental","pubTime":"2025-11-20 02:36","pubTimestamp":1763577361,"startTime":"0","endTime":"0","summary":"The latest announcement from Zymeworks (NasdaqGS:ZYME) centers on the positive topline readout from its Phase 3 HERIZON-GEA-01 trial for Ziihera. The trial delivered notable clinical benefit in HER2-positive gastroesophageal cancer patients.\nSee our latest analysis for Zymeworks.\nRecent weeks have seen Zymeworks making headlines by announcing a $125 million share repurchase plan, refreshing its board, and securing a four-year high in its share price after releasing strong clinical data for...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zyme/zymeworks/news/a-look-at-zymeworks-zyme-valuation-after-breakthrough-phase","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zyme/zymeworks/news/a-look-at-zymeworks-zyme-valuation-after-breakthrough-phase","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","ZYME","DCF"],"gpt_icon":0},{"id":"2584284959","title":"Evercore ISI Sticks to Its Buy Rating for Zymeworks (ZYME)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584284959","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584284959?lang=en_us&edition=fundamental","pubTime":"2025-11-19 23:36","pubTimestamp":1763566618,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Jonathan Miller from Evercore ISI reiterated a Buy rating on Zymeworks, with a price target of $33.00. Miller cover...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/evercore-isi-sticks-to-its-buy-rating-for-zymeworks-zyme-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/evercore-isi-sticks-to-its-buy-rating-for-zymeworks-zyme-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZYME"],"gpt_icon":0},{"id":"2584630945","title":"Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME) and Medtronic (MDT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584630945","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584630945?lang=en_us&edition=fundamental","pubTime":"2025-11-19 19:50","pubTimestamp":1763553010,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Zymeworks (ZYME – Research Report) and Medtronic (...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-zymeworks-zyme-and-medtronic-mdt-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-zymeworks-zyme-and-medtronic-mdt-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1244550577.SGD","LU0265550946.USD","LU1057294990.SGD","LU1244550221.USD","LU2023251221.USD","LU0070302665.USD","LU0158827948.USD","LU1989771016.USD","LU1023059063.AUD","MDT","LABU","IE00B3T34201.USD","LU2089284900.SGD","HCSG","LU0211326839.USD","LU2028103732.USD","LU1571399168.USD","LU2112291526.USD","BK4581","IE00BFXG1179.USD","BK4588","LU0314106906.USD","BK4533","XLV","LU0496365809.HKD","LU0122379950.USD","IE00BQXX3F31.USD","LU1116320901.HKD","LU0072461881.USD","XBI","LU1983299246.USD","BK4139","LU0976567544.SGD","LU0320765489.SGD","BK4082","LU0029874061.USD","LU0128526141.USD","LU2271345857.HKD","LU0208291251.USD","LU0432979614.USD","LU1061106388.HKD","BK4566","LU0162691827.USD","LU1116320737.USD","LU1506573853.SGD","IE000M9KFDE8.USD","IE00BQXX3D17.EUR","LU0158827781.USD","LU2089984988.USD","ZYME"],"gpt_icon":0},{"id":"2584431179","title":"Zymeworks Inc : Stifel Raises Target Price to $40 From $30","url":"https://stock-news.laohu8.com/highlight/detail?id=2584431179","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584431179?lang=en_us&edition=fundamental","pubTime":"2025-11-19 19:46","pubTimestamp":1763552778,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nFWN3WV0L7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZYME","BK4139"],"gpt_icon":0},{"id":"2584463918","title":"U.S. RESEARCH ROUNDUP-Amgen, Crowdstrike, Micron Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2584463918","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584463918?lang=en_us&edition=fundamental","pubTime":"2025-11-19 15:17","pubTimestamp":1763536636,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Amgen, Crowdstrike, Micron TechnologyNov 19 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Amgen,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nL4N3WV0GT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065170008.USD","PCVX","NUVB","ZYME","LU0820561818.USD","BK4548","VTVT","RAPP","CRWD","SG9999014542.SGD","89888","BK1609","ENR","TERN","PRAX","ZION","LU2498475776.HKD","RARE","BK4549","KNTK","LU0266013472.USD","LU0289739699.SGD","OLMA","LGIH","ARWR","DKS","LU0079474960.USD","LU2756315664.SGD","HD","FCX","MU","INCY","COTY","WCC","AMGN","BRBR","LU0127658192.USD","DASH","LU0353189763.USD","LU1585245621.USD","SG9999015358.SGD","SION","MBI","UHS","LU2039709279.SGD","IPAR"],"gpt_icon":1},{"id":"2584935801","title":"Zymeworks Shares Fall 1.7% Premarket Day After Climbing to Four-Year High","url":"https://stock-news.laohu8.com/highlight/detail?id=2584935801","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584935801?lang=en_us&edition=fundamental","pubTime":"2025-11-18 18:16","pubTimestamp":1763460975,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nFWN3WU0P5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZYME","BK4139"],"gpt_icon":0},{"id":"2584498981","title":"Zymeworks Stock (ZYME) Soars on Positive Results for Cancer Drug Ziihera, Top Analysts Boost Price Targets","url":"https://stock-news.laohu8.com/highlight/detail?id=2584498981","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584498981?lang=en_us&edition=fundamental","pubTime":"2025-11-18 15:33","pubTimestamp":1763451198,"startTime":"0","endTime":"0","summary":"Zymeworks ($ZYME) stock rallied 29% on Monday, after the clinical-stage biotechnology company announced positive Phase 3 trial results for its gast...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/zymeworks-stock-zyme-soars-on-positive-results-for-cancer-drug-ziihera-top-analysts-boost-price-targets?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/zymeworks-stock-zyme-soars-on-positive-results-for-cancer-drug-ziihera-top-analysts-boost-price-targets?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZYME"],"gpt_icon":0},{"id":"2584828985","title":"BRIEF-Zymeworks Says Authorizes $125 Million Share Repurchase Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2584828985","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584828985?lang=en_us&edition=fundamental","pubTime":"2025-11-18 14:04","pubTimestamp":1763445843,"startTime":"0","endTime":"0","summary":"BRIEF-Zymeworks Says Authorizes $125 Million Share Repurchase PlanNov 18 (Reuters) - Zymeworks Inc ZYME.O:ZYMEWORKS ANNOUNCES STRATEGIC INITIATIVE TO OPTIMIZE VALUE OF LICENSED PRODUCTS BY BUILDING A ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nTUA5PCZPB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZYME"],"gpt_icon":0},{"id":"2584851985","title":"Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2584851985","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584851985?lang=en_us&edition=fundamental","pubTime":"2025-11-18 14:01","pubTimestamp":1763445681,"startTime":"0","endTime":"0","summary":"Zymeworks Inc. has appointed Scott Platshon as Acting Chief Investment Officer. Platshon will report directly to Chair and CEO Kenneth Galbraith and oversee management of future cash flows, asset aggregation strategy, and portfolio development. He has stepped down from the Board of Directors and will continue his role as Partner at EcoR1 Capital, LLC.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zymeworks Inc. published the original content used to generate this news brief via GlobeNewswire  on November 18, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL3pJMT3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZYME","IE00B64PRP62.GBP","LU2210150020.SGD","BK4112","LU2210149790.SGD","BK4139","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BKPKM429.USD","NDAQ","LU2095319765.USD","BK4588","BK4585"],"gpt_icon":0},{"id":"2584983049","title":"Zymeworks Inc. Announces Strategic Initiative to Optimize Future Cash Flows Through Diversified Revenue-Generating Assets, Capital Allocation, and $125 Million Share Repurchase Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2584983049","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584983049?lang=en_us&edition=fundamental","pubTime":"2025-11-18 14:00","pubTimestamp":1763445627,"startTime":"0","endTime":"0","summary":"Zymeworks Inc. Announces Strategic Initiative to Optimize Future Cash Flows Through Diversified Revenue-Generating Assets, Capital Allocation, and $125 Million Share Repurchase Plan. Zymeworks Inc. announced a new strategic initiative focused on optimizing future cash flows from its licensed products, including Ziihera , pasritamig, and other healthcare assets. The company plans to build a diversified portfolio of revenue-generating assets by combining internal innovation, licensing, and strategic acquisitions. Zymeworks aims to reinvest proceeds from its royalty streams into assets with lower traditional biotechnology risk profiles and return excess capital to shareholders through share repurchase programs or special dividends. The company also authorized a new $125 million share repurchase plan and will continue to seek financial contributions from partnerships and collaborations to support ongoing R&D investments while maintaining disciplined capital allocation.Disclaimer: This news","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL8ryH2X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZYME","BK4588","LU0314104364.USD","IE00B3QW5Z07.USD","BK4112","LU2095319765.USD","BK4139","LU2210149790.SGD","IE00BGHQF748.EUR","BK4585","IE00BKPKM429.USD","NDAQ","LU2210150020.SGD","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2584985848","title":"Zymeworks Inc - Authorizes $125 Mln Share Repurchase Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2584985848","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584985848?lang=en_us&edition=fundamental","pubTime":"2025-11-18 14:00","pubTimestamp":1763445600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nTUA5PCZPB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZYME","BK4139"],"gpt_icon":0},{"id":"2584983449","title":"Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2584983449","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584983449?lang=en_us&edition=fundamental","pubTime":"2025-11-18 14:00","pubTimestamp":1763445600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nTUA5PCZPB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZYME"],"gpt_icon":0},{"id":"1182455974","title":"Stock Track | Zymeworks Plunges 9.29% Despite Positive Cancer Drug Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1182455974","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182455974?lang=en_us&edition=fundamental","pubTime":"2025-11-18 09:05","pubTimestamp":1763427904,"startTime":"0","endTime":"0","summary":"Zymeworks Inc. (NASDAQ: ZYME) experienced a surprising 9.29% plunge in after-hours trading on Monday, despite announcing positive topline results from its Phase 3 HERIZON-GEA-01 trial for its cancer...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"12b9cc00d05cc390c8f725385f7a4061","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ZYME"],"gpt_icon":0},{"id":"2584726675","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2584726675","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584726675?lang=en_us&edition=fundamental","pubTime":"2025-11-18 02:57","pubTimestamp":1763405837,"startTime":"0","endTime":"0","summary":"Zymeworks (ZYME) said Monday its phase 3 trial evaluating Ziihera plus chemotherapy as a first-line treatment in gastroesophageal adenocarcinoma showed a statistically significant improvement in progr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4532","BK4139","IE00BN0W2W23.USD","LU0889565916.HKD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","LU0320765992.SGD","BK4533","ANVS","LU0823416689.USD","LU0109394709.USD","ZYME","JAZZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zymeworks.com","stockEarnings":[{"period":"1week","weight":-0.0133},{"period":"1month","weight":0.4332},{"period":"3month","weight":0.5852},{"period":"6month","weight":1.0418},{"period":"1year","weight":0.9809},{"period":"ytd","weight":0.7671}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.035465},{"month":2,"riseRate":0.25,"avgChangeRate":-0.068196},{"month":3,"riseRate":0.375,"avgChangeRate":-0.032876},{"month":4,"riseRate":0.625,"avgChangeRate":0.039222},{"month":5,"riseRate":0.333333,"avgChangeRate":0.017913},{"month":6,"riseRate":0.555556,"avgChangeRate":-0.046141},{"month":7,"riseRate":0.444444,"avgChangeRate":-0.030946},{"month":8,"riseRate":0.888889,"avgChangeRate":0.104131},{"month":9,"riseRate":0.444444,"avgChangeRate":0.038592},{"month":10,"riseRate":0.666667,"avgChangeRate":0.043198},{"month":11,"riseRate":0.777778,"avgChangeRate":0.135367},{"month":12,"riseRate":0.555556,"avgChangeRate":0.003025}],"exchange":"NASDAQ","name":"ZYMEWORKS INC (US)","nameEN":"ZYMEWORKS INC (US)"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ZYMEWORKS INC (US)(ZYME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ZYMEWORKS INC (US)(ZYME) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ZYMEWORKS INC (US),ZYME,ZYMEWORKS INC (US)股票,ZYMEWORKS INC (US)股票老虎,ZYMEWORKS INC (US)股票老虎国际,ZYMEWORKS INC (US)行情,ZYMEWORKS INC (US)股票行情,ZYMEWORKS INC (US)股价,ZYMEWORKS INC (US)股市,ZYMEWORKS INC (US)股票价格,ZYMEWORKS INC (US)股票交易,ZYMEWORKS INC (US)股票购买,ZYMEWORKS INC (US)股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ZYMEWORKS INC (US)(ZYME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ZYMEWORKS INC (US)(ZYME) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}